Position in NTLA
as of Jun 30, 2026
· filed Aug 10, 2026
Position Value
$1,037,923
+$433,127 QoQ
Shares Held
61,343
+30.0% QoQ
Ownership
0.044%
of shares outstanding
% of Portfolio
0.54%
of 13F equity value
Holder Rank
#120
of 329 holders
Holding Since
Mar 2024
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NTLA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Gen-Wealth Partners Inc holds $1,476,128 across 15 Biotechnology names. NTLA ranks #1 (70.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NTLA |
Intellia Therapeutics, Inc.
This page
|
61,343 | $1,037,923 | |
| 2 | ARGX |
Argenx SE
|
230 | $213,387 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
172 | $107,248 | |
| 4 | ATNM |
Actinium Pharmaceuticals, Inc.
|
105,111 | $103,008 | |
| 5 | TNXP |
Tonix Pharmaceuticals Holding Corp.
|
533 | $6,801 | |
| 6 | QNCX |
Quince Therapeutics, Inc.
|
165 | $3,001 | |
| 7 | VKTX |
Viking Therapeutics, Inc.
|
29 | $1,131 | |
| 8 | CRSP |
CRISPR Therapeutics AG
|
16 | $872 |
All Filings in NTLA
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,037,923 | 61,343 | Shares | Sole | 2026-08-10 | |
| 2026-03-31 | $604,796 | 47,176 | Shares | Sole | 2026-05-08 | |
| 2025-12-31 | $299,501 | 33,315 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $91,582 | 5,303 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $384 | 41 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $291 | 41 | Shares | Sole | 2025-05-13 | |
| 2024-12-31 | $478 | 41 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $842 | 41 | Shares | Sole | 2024-11-13 | |
| 2024-06-30 | $917 | 41 | Shares | Sole | 2024-08-13 | |
| 2024-03-31 | $1,127 | 41 | Shares | Sole | 2024-05-15 | |
| No filing history on record for this holder in this stock. | ||||||